CanSino Biologics Inc. (HKG:6185)

Hong Kong · Delayed Price · Currency is HKD

33.94

+1.74 (5.40%)

At close: Mar 6, 2026

Revenue by Segment

Financials in millions CNY. Fiscal year is January - December.

Millions CNY. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019	Dec '18 Dec 31, 2018	Dec '17 Dec 31, 2017	Dec '16 Dec 31, 2016
Research and Development of Vaccine Products for Human Use		846.34M	357.08M	1.03B	4.30B	24.89M
Research and Development of Vaccine Products for Human Use Growth		137.01%	-65.49%	-75.94%	17174.82%	59.43%
Total		846.34M	357.08M	1.03B	4.30B	24.89M
Total Growth		137.01%	-65.49%	-75.94%	17174.82%	59.43%

Revenue by Geography

Financials in millions CNY. Fiscal year is January - December.

Millions CNY. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019	Dec '18 Dec 31, 2018	Dec '17 Dec 31, 2017	Dec '16 Dec 31, 2016
People's Republic of China (PRC)		795.16M	-	812.76M	-	-
Overseas		29.72M	-	218.28M	-	-
Total		824.88M	-	1.03B	-	-

Source: S&P Global Market Intelligence.